Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apyx Medical (APYX) Long-Term Debt Repayments (2016 - 2018)

Apyx Medical's Long-Term Debt Repayments history spans 8 years, with the latest figure at $5.4 million for Q4 2018.

  • For Q4 2018, Long-Term Debt Repayments rose 1189.0% year-over-year to $5.4 million; the TTM value through Sep 2019 reached $5.4 million, up 336.73%, while the annual FY2023 figure was $11.0 million, N/A changed from the prior year.
  • Long-Term Debt Repayments reached $5.4 million in Q4 2018 per APYX's latest filing, up from -$2.8 million in the prior quarter.
  • In the past five years, Long-Term Debt Repayments ranged from a high of $6.6 million in Q4 2014 to a low of -$3.6 million in Q1 2014.
  • Average Long-Term Debt Repayments over 5 years is $281350.0, with a median of -$59000.0 recorded in 2016.
  • The largest YoY upside for Long-Term Debt Repayments was 11162.71% in 2014 against a maximum downside of 10664.71% in 2014.
  • A 5-year view of Long-Term Debt Repayments shows it stood at $6.6 million in 2014, then crashed by 106.31% to -$419000.0 in 2015, then soared by 85.68% to -$60000.0 in 2016, then surged by 796.67% to $418000.0 in 2017, then soared by 1189.0% to $5.4 million in 2018.
  • Per Business Quant, the three most recent readings for APYX's Long-Term Debt Repayments are $5.4 million (Q4 2018), -$2.8 million (Q3 2018), and $180000.0 (Q2 2018).